- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
December 10th, 2007
Arch Venture Partners, the 21-year-old venture capital firm whose Seattle area investments include Allozyne, Trubion Pharmaceuticals and VLST, has raised a $400 million venture fund.
It is the firm's seventh fund. The money will be invested in early-stage companies in the biotechnology, advanced materials, nanotechnology and semiconductor sectors.
|Related News Press|
Nanostart AG: Capital increase and realignment December 31st, 2015
Discovery of the specific properties of graphite-based carbon materials February 6th, 2016
Study reveals how herpes virus tricks the immune system February 5th, 2016
Hepatitis virus-like particles as potential cancer treatment February 5th, 2016